P-1075

P-1075
Clinical data
Other namesP1075
Drug classATP-sensitive potassium channel opener; Vasodilator; Antihypertensive agent
ATC code
  • None
Identifiers
  • 1-cyano-2-(2-methylbutan-2-yl)-3-pyridin-3-ylguanidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.217.104 Edit this at Wikidata
Chemical and physical data
FormulaC12H17N5
Molar mass231.303 g·mol−1
3D model (JSmol)
  • CCC(C)(C)N=C(NC#N)NC1=CN=CC=C1
  • InChI=1S/C12H17N5/c1-4-12(2,3)17-11(15-9-13)16-10-6-5-7-14-8-10/h5-8H,4H2,1-3H3,(H2,15,16,17)
  • Key:HKZNADVVGXKQDL-UHFFFAOYSA-N

P-1075 is an ATP-sensitive potassium channel opener which was under development for the treatment of androgenic alopecia (pattern hair loss), arrhythmias, and ischemic heart disorders but was never marketed. It has been found to stimulate cultured hair follicles and to promote hair growth in balding stump-tailed macaques. The drug was being developed by AstraZeneca and LEO Pharma. It reached phase 2 clinical trials for alopecia and the preclinical research stage of development for arrhythmia and ischemic heart disorders prior to the discontinuation of its development by 2000. In terms of chemical structure, P-1075 is a guanidine derivative and a more potent analogue of pinacidil.

See also

References

  1. 1 2 3 "P 1075". AdisInsight. 3 November 2000.
  2. 1 2 3 "Delving into the Latest Updates on P-1075 with Synapse". Synapse. 20 July 2025. Retrieved 24 July 2025.
  3. 1 2 3 Buhl AE, Conrad SJ, Waldon DJ, Brunden MN (July 1993). "Potassium channel conductance as a control mechanism in hair follicles". The Journal of Investigative Dermatology. 101 (1 Suppl): 148S–152S. doi:10.1111/1523-1747.ep12363290. PMID 8326149.
  4. 1 2 Messenger AG, Rundegren J (February 2004). "Minoxidil: mechanisms of action on hair growth". The British Journal of Dermatology. 150 (2): 186–194. doi:10.1111/j.1365-2133.2004.05785.x. PMID 14996087.
  5. 1 2 Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S (May 2012). "Minoxidil use in dermatology, side effects and recent patents". Recent Patents on Inflammation & Allergy Drug Discovery. 6 (2): 130–136. doi:10.2174/187221312800166859. PMID 22409453. Other potassium channel openers, like diazoxide [39, 40] and pinacidil [41] can cause hypertrichosis in humans as well as minoxidil. In balding macaques minoxidil, cromakalin and P-1075 (a pinacidil analogue) stimulate hair growth in about 20 weeks of topical treatment, whereas a fourth potassium channel opener, called RP49356, is not effective [42]. Harmon et al. suggested that minoxidil, diazoxide, cromakalin and pinacidil increased uptake of thymidine in hair growth cultures of mouse vibrissae follicles [43].